329 related articles for article (PubMed ID: 31591209)
21. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
22. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
23. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
[TBL] [Abstract][Full Text] [Related]
24. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
25. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
26. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
27. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
28. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Muvarak NE; Chowdhury K; Xia L; Robert C; Choi EY; Cai Y; Bellani M; Zou Y; Singh ZN; Duong VH; Rutherford T; Nagaria P; Bentzen SM; Seidman MM; Baer MR; Lapidus RG; Baylin SB; Rassool FV
Cancer Cell; 2016 Oct; 30(4):637-650. PubMed ID: 27728808
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
[TBL] [Abstract][Full Text] [Related]
30. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D
Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
Lim D; Ngeow J
Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207
[TBL] [Abstract][Full Text] [Related]
32. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
33. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
34. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
35. Resurrection of PARP Inhibitors in Breast Cancer.
Lyons TG; Robson ME
J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
[TBL] [Abstract][Full Text] [Related]
36. Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
De Summa S; Pinto R; Pilato B; Sambiasi D; Porcelli L; Guida G; Mattioli E; Paradiso A; Merla G; Micale L; De Nittis P; Tommasi S
Cell Death Dis; 2014 Feb; 5(2):e1076. PubMed ID: 24556691
[TBL] [Abstract][Full Text] [Related]
37. Abrogation of KLF5 sensitizes
Zhang Z; Liu Y; Xu Y; Xu Z; Jia J; Jin Y; Wang W; Liu L
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):576-585. PubMed ID: 38433576
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
Albert JM; Cao C; Kim KW; Willey CD; Geng L; Xiao D; Wang H; Sandler A; Johnson DH; Colevas AD; Low J; Rothenberg ML; Lu B
Clin Cancer Res; 2007 May; 13(10):3033-42. PubMed ID: 17505006
[TBL] [Abstract][Full Text] [Related]
39. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.
Verma P; Zhou Y; Cao Z; Deraska PV; Deb M; Arai E; Li W; Shao Y; Puentes L; Li Y; Patankar S; Mach RH; Faryabi RB; Shi J; Greenberg RA
Nat Cell Biol; 2021 Feb; 23(2):160-171. PubMed ID: 33462394
[TBL] [Abstract][Full Text] [Related]
40. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
